Show simple item record

dc.contributor.authorFernández Chávez, Abelardo Claudio
dc.contributor.authorGarcía Comas, Luis
dc.contributor.authorManzano Espinosa, Luis
dc.contributor.authorYuste Lobo, José
dc.contributor.authorCorral Pazos de Provens, Octavio
dc.contributor.authorAranaz Andrés, Jesús María
dc.identifier.citationEur J Clin Microbiol Infect Dis 2022 Feb;41(2):227-234.es_ES
dc.description.abstractThe major goals of the study were to describe the invasive pneumococcal disease (IPD) cases due to erythromycin-resistant serotypes and to evaluate the association between these cases and recent macrolide use in individuals aged over 59 years. We selected cases of IPD reported between 2007 and 2016 in persons aged over 59 years living in the Community of Madrid (CM). We followed the European Committee on Antimicrobial Susceptibility Testing (EUCAST). The explanatory variables (age, sex, year of onset of symptoms, clinical presentation, serotypes, vaccination status) were taken from the Mandatory Notification System for Infectious Diseases System and from the Vaccination Information System. The cases were classified as either included in the 13-valent pneumococcal conjugate vaccine (PCV13) or not (nonPCV13). Associations between cases due to erythromycin-resistant serotypes and previous macrolide use (total, long and short-term) were adjusted with a logistic regression multivariate analysis. A total of 1,831 cases were identified, of whom 408 were erythromycin-resistant serotypes. PCV13 cases were associated with previous macrolide use (OR: 5.07), particularly long-acting types (OR: 8.61). NonPCV13 cases were associated with the use of total macrolides (OR: 3.48) and long-acting macrolides (OR: 4.26) suggesting that PCV13 did not reduce the IPD cases in patients with previous use of macrolides. Our results confirmed that previous macrolide consumption was associated with the presence of IPD due to erythromycin-resistant serotypes. The risk was higher with the use of long-term macrolides.es_ES
dc.publisherSpringer es_ES
dc.subjectInvasive pneumococcal diseasees_ES
dc.subjectPneumococcal conjugate vaccineses_ES
dc.subjectReduced antibiotic susceptibilityes_ES
dc.titleImpact of previous macrolide use on invasive pneumococcal disease due to erythromycin-resistant serotypes in adults over 59 years of agees_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.journalEuropean Journal of Clinical Microbiology & Infectious Diseases: official publication of the European Society of Clinical Microbiologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional